AB Science
A8D
Company Profile
Business description
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
Contact
3, Avenue George V
Paris75008
FRAT: +33 147200014
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,478.70 | 3.10 | 0.04% |
| CAC 40 | 7,665.62 | 142.25 | -1.82% |
| DAX 40 | 22,380.19 | 459.37 | -2.01% |
| Dow JONES (US) | 45,577.47 | 443.96 | -0.96% |
| FTSE 100 | 9,918.33 | 145.17 | -1.44% |
| HKSE | 25,277.32 | 223.26 | -0.88% |
| NASDAQ | 21,647.61 | 443.08 | -2.01% |
| Nikkei 225 | 51,788.98 | 1,583.55 | -2.97% |
| NZX 50 Index | 12,830.74 | 159.25 | -1.23% |
| S&P 500 | 6,506.48 | 100.01 | -1.51% |
| S&P/ASX 200 | 8,292.20 | 8.70 | 0.11% |
| SSE Composite Index | 3,957.05 | 49.50 | -1.24% |